Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 408 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Suppression Clear all
Completed Phase 2 Interventional

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

NCT00000912
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
44
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Study to Assess Safety

NCT03645499
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Topical TA-102 A, Topical TA-102 B, Topical TA-102 C, Topical TA-102 D, Topical TA-102 E
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

NCT00654147
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir & Lopinavir/ritonavir, Raltegravir and emtricitabine/tenofovir
Drug
Lead sponsor
Margaret A. Fischl, M.D.
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Active and Passive Music Therapy Interventions

NCT03362944
View directory record Official record
Conditions
Autonomic Nervous System Imbalance, Hypothalamic Pituitary Adrenal Axis Suppression
Interventions
Active Music Therapy, Passive Music Therapy
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 34 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women

NCT01586000
View directory record Official record
Conditions
Suppression of Ovulation
Interventions
10 µg/day E2 with NES 200® µg/day, 20 µg/day E2 with NES 200® µg/day, 40 µg/day E2 with NES 200® µg/day
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
8
States / cities
Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation (DBS) for the Suppression of Tremor

NCT02087046
View directory record Official record
Conditions
Tremor, Action Tremor, Essential Tremor, Tremor, Limb
Interventions
ANS Totally Implantable Deep Brain Stimulation System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Loma Linda, California • Pasadena, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib to Treat Significant Complication of HSCT

NCT01929980
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation, Refractory Autoimmune Cytopenia(s)
Interventions
Bortezomib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Months to 29 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

NCT00116844
View directory record Official record
Conditions
Infections, Herpesviridae
Interventions
Valaciclovir, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
17
States / cities
Carmichael, California • Davis, California • Riverside, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Phase 4 Interventional

4-Day-A-Week Treatment Plan for HIV Infected Adolescents

NCT00068809
View directory record Official record
Conditions
HIV Infections
Interventions
Short Cycle Antiretroviral Therapy
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Peer-based Mobile-health Intervention to Increase Access & Adherence to Hepatitis C Treatment & HIV Viral Suppression

NCT02772328
View directory record Official record
Conditions
Hepatitis C, HIV, Risk Reduction Behavior
Interventions
Peer Mentor
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Electronic Cigarette (ECIG) Liquid Vehicles on ECIG Acute Effects

NCT02500615
View directory record Official record
Conditions
Nicotine Exposure, Nicotine Withdrawal Suppression
Interventions
ECIG liquid vehicles
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

Spreading Depolarization and Ketamine Suppression

NCT02501941
View directory record Official record
Conditions
Cortical Spreading Depolarization, Cortical Spreading Depression, Subarachoid Hemorrhage, Traumatic Brain Injury
Interventions
ketamine
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 26, 2026, 1:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Testing a Possible Cause of Reduced Ability of Children to Process Speech in Noise

NCT00001957
View directory record Official record
Conditions
Central Auditory Disease, Healthy
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

NCT01842139
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions
basiliximab, WT1 126-134 peptide vaccine, Montanide ISA 51 VG, poly ICLC, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 26, 2026, 1:04 PM EDT
Not listed No phase listed Observational

Appetite Suppression / Hormone Study Control Group

NCT02029677
View directory record Official record
Conditions
Morbid Obesity, Bariatric Surgery Patient
Interventions
Not listed
Lead sponsor
Oregon Weight Loss Surgery, LLC
Other
Eligibility
18 Years to 69 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

NCT00158860
View directory record Official record
Conditions
Herpes Genitalis
Interventions
Valaciclovir, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 26, 2026, 1:04 PM EDT
Recruiting Phase 3 Interventional

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

NCT01492972
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation, Androgen Suppression Therapy
Radiation · Drug
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older · Male only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
4
States / cities
Scottsdale, Arizona • Warrenville, Illinois • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 26, 2026, 1:04 PM EDT
Recruiting Phase 2 Interventional

Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough

NCT06960759
View directory record Official record
Conditions
Chronic Cough (CC), Refractory Chronic Cough, Unexplained Chronic Cough
Interventions
BCS+inactive, BCS+active
Behavioral · Combination Product
Lead sponsor
University of Montana
Other
Eligibility
18 Years to 99 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Aurora, Colorado • Atlanta, Georgia • Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

Bone Marrow Transplant With Abatacept for Non-Malignant Diseases

NCT01917708
View directory record Official record
Conditions
Hurler Syndrome, Fanconi Anemia, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Shwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia, Thalassemia Major, Hemophagocytic Lymphohistiocytosis, Sickle Cell Disease
Interventions
Abatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 26, 2026, 1:04 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Therapeutic Omegas for Triglyceride Suppression

NCT04349475
View directory record Official record
Conditions
Pregnancy
Interventions
Intervention Omega 3 Supplementation, Placebo Soybean Oil
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
0 Years to 39 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

NCT03058744
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-118 Lotion, HP Monad Lotion, Ultravate Cream, Tazorac Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Anaheim, California • Encino, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Not applicable Interventional Results available

Suppression of HIV 1 RNA in People Living With HIV

NCT02363387
View directory record Official record
Conditions
HIV
Interventions
Incentives for Viral Suppression, Standard HIV Medical Care
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 26, 2026, 1:04 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging

NCT04275453
View directory record Official record
Conditions
Healthy
Interventions
FDG, Ketone Drink, Ketogenetic Diet
Drug · Dietary Supplement · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 26, 2026, 1:04 PM EDT
Completed Not applicable Interventional

Scale-up of an Internet-Delivered Study for HIV+ Men

NCT02023580
View directory record Official record
Conditions
HIV
Interventions
Video treatments
Behavioral
Lead sponsor
Public Health Solutions
Other
Eligibility
18 Years and older · Male only
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 26, 2026, 1:04 PM EDT